Cytomx Therapeutics, Inc. · NASDAQ:CTMX
Cytomx Therapeutics — Bank of America Merrill Lynch 2018 Health Care Conference
26 slides from Cytomx Therapeutics's conference presentation, May 16, 2018
Slide 1: Reinventing Therapeutic Antibodies for the Treatment of Cancer
Bank of America Merrill Lynch 2018 Health Care Conference Reinventing Therapeutic Antibodies for the Treatment of Cancer May 17, 2018 Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation may contain projections and other forward-looking statements regarding future events. All statements other than statements of historical facts contained in this presentation, including statements regarding
Slide 3: Leveraging Our Innovative Probody Platform to Build a Pipeline of Differentiated Cancer Therapies
Leveraging Our Innovative Probody Platform to Build a Pipeline of Differentiated Cancer Therapies Maturing Partnerships Two clinical stage partnered programs BMS-986249 (anti-CTLA-4): Phase 1/2 trial ongoing CX-2029 (CD71-directed PDC co-developed with AbbVie): CytomX filed IND in April 2018 PROBODY
Slide 4: Probody Therapeutics are Designed to be Activated in the Tumor Microenvironment
Probody Therapeutics are Designed to be Activated in the Tumor Microenvironment ANTI-CANCER ANTIBODY LINKER MASKING PEPTIDE PROTEASES TUMOR TUMOR TUMOR
Slide 5: Deep and Differentiated Probody Pipeline with Initial Clinical Data Read Outs in 2018
PRODUCT CANDIDATE LEAD OPTIMIZATION IND-ENABLING PHASE 1/2 COMMERCIAL RIGHTS CX-072 CX-2009 BMS-986249 CX-2029 CX-188 T Cell Bispecific Additional PDCs, IO, Pb-TCBs Deep and Differentiated Probody Pipeline with Initial Clinical Data Read Outs in 2018 Immunotherapies Probody Drug Conjugates T Cell En
Slide 6: CX-072: PD-L1 Probody Therapeutic
CX-072: PD-L1 Probody Therapeutic
Slide 7: Full Potential for Combination Immunotherapy is Limited by Immune-Related Toxicities
Full Potential for Combination Immunotherapy is Limited by Immune-Related Toxicities DERMATITIS PNEUMONITIS HEPATITIS THROMBOEMBOLIC OCULAR TOXICITY HYPOPHYSITIS THYROIDITIS COLITIS, DIARRHEA NEUROPATHY 1. Larkin et al., NEJM, July 2015. Nivo + Ipi toxicity is synergistic Nivolumab Mono melanoma Ipi
Slide 8: CX-072 as a Potential Centerpiece of Combination Cancer Therapy
CX-072 as a Potential Centerpiece of Combination Cancer Therapy CX-072 PD-L1 PROBODY THERAPEUTIC Checkpoint Inhibitors E.g. Yervoy® Probody Tx PDCs Pb-TCBs Other Cancer Immuno- therapies Kinase Inhibitors E.g. Zelboraf® ADCs Validated target Well-established efficacy & safety for class
Slide 9: CX-072 Preclinical Proof of Concept
Non-binding Control Antibody Parent PD-L1 Antibody CX-072 PD-L1 Probody Tx Tumor CX-072 Preclinical Proof of Concept Antitumor efficacy, improved safety, localization to tumor TUMOR GROWTH SAFETY Induction of Autoimmunity Similar Efficacy Tx Tx Autoimmunity Reduced Localizes to Tumor Prevents Bindin
Slide 10: PROCLAIM-072: Phase 1/2 CX-072 Assessment as Monotherapy and in Combination
PROCLAIM-072: Phase 1/2 CX-072 Assessment as Monotherapy and in Combination Inclusion: Unselected cancer types Dose: 0.3 – 30 mg/kg + IPI (3 and 10 mg/kg) A1: DOSE ESCALATION Inclusion: PD naïve, unselected cancer types Dose: 0.03 – 30 mg/kg A2: MANDATORY BIOPSY D: EXPANSION COHORT Inclusion: Select
Slide 11: CX-072 Clinical Data Presentation 2018 ASCO Annual Meeting Abstract 3071
CX-072 Clinical Data Presentation 2018 ASCO Annual Meeting Abstract 3071 [Poster 285] Preliminary Results of the First-In-Human, Dose-Finding PROCLAIM-072 Trial of the PD-L1 Probody Therapeutic CX-072 as Monotherapy in Patients with Advanced Solid Tumors Presenter:Karen A. Autio, M.D., MSc., Memoria
Slide 12: Initial CX-072 Clinical Data: Activity in a Triple Negative Breast Cancer Patient
CX-072 remains masked and stable systemically Reduction of Tumor Burden Patient Profile 39 years old, PD-L1 negative, TMB low, Microsatellite Stable Initial CX-072 Clinical Data: Activity in a Triple Negative Breast Cancer Patient Three prior lines of therapy Post mastectomy and left reconstruction
Slide 13: CX-072 Clinical Data Presentation 2018 ASCO Annual Meeting Abstract 3072
CX-072 Clinical Data Presentation 2018 ASCO Annual Meeting Abstract 3072 [Poster 286] Preliminary Interim Results of the First-In-Human, Dose-Finding PROCLAIM-072 Trial of the PD-L1 Probody Therapeutic CX-072 in Combination with Ipilimumab in Patients with Advanced Solid Tumors Presenter:Rachel E. S
Slide 14: PROCLAIM-072: Phase 1/2 CX-072 Assessment as Monotherapy and in Combination
PROCLAIM-072: Phase 1/2 CX-072 Assessment as Monotherapy and in Combination Inclusion: Unselected cancer types Dose: 0.3 – 30 mg/kg + IPI (3 and 10 mg/kg) A1: DOSE ESCALATION Inclusion: PD naïve, unselected cancer types Dose: 0.03 – 30 mg/kg A2: MANDATORY BIOPSY D: EXPANSION COHORT Inclusion: Select
Slide 15: CX-2009: CD166-Directed Probody Drug Conjugate
CX-2009: CD166-Directed Probody Drug Conjugate
Slide 16: Probody Technology Enables Selection of Better Antibody Drug Conjugate Targets
Her2 Probody Technology Enables Selection of Better Antibody Drug Conjugate Targets PDC Targets May Have More Attractive Attributes: CD166 CD71 Her2 CD30 Mesothelin Folate Receptor CD166 PDC Targets ADC Targets ADC Targets are Limited Based on Healthy Tissue Expression: More patients More indication
Slide 17: CX-2009: A Probody Drug Conjugate Targeting CD166
CX-2009: A Probody Drug Conjugate Targeting CD166 Preclinical Proof of Concept CX2009 CD166 Antibody DM4 Payload V1 V2 C1 C2 C3 Cancer Cell Substrate Linker Mask Protease GLP Toxicity Study Results: Dosed up to 15 mg/kg in cynos Observed toxicity consistent with typical DM4 payload toxicity
Slide 18: PROCLAIM-CX-2009: CD166-Directed PDC Phase 1/2 Clinical Trial Design
2017 2018 PROCLAIM-CX-2009: CD166-Directed PDC Phase 1/2 Clinical Trial Design Breast cancer Castration-resistant prostate cancer Cholangiocarcinoma Endometrial cancer Head and neck cancer Non-small cell lung cancer Ovarian cancer Lung cancer Breast cancer Ovarian cancer Seven CD166+ tumor types in
Slide 19: Partnered Programs
ow CYTOMX THERAPEUTICS Partnered Programs
Slide 20: Alliances Have Brought Significant Capital into CytomX and Broadened Our Pipeline
Alliances Have Brought Significant Capital into CytomX and Broadened Our Pipeline of Probody Therapeutics 10 oncology, 2 non-oncology targets CTLA-4 Probody Tx in Ph. 1 $287 million earned to date $4.8 billion in potential milestones, tiered royalties up to low-double digits EGFR-TCB + 3 additional
Slide 21: CD71 is a High Potential Target for a Probody Drug Conjugate
CD71 is a High Potential Target for a Probody Drug Conjugate Ubiquitously expressed on dividing, normal and malignant cells Mediates iron uptake required for cell division Professional internalizing protein: often used as a positive control in ADC experiments Expression in normal dividing cells proh
Slide 22: Probody Platform Has the Potential to Enable CD71 as a Drug Conjugate Target
Probody Platform Has the Potential to Enable CD71 as a Drug Conjugate Target PDC regresses tumors after a single dose in mice PDC has efficacy across almost all preclinical models Models tested 42 Regression or stasis 30 (71%) Growth inhibition 10 (24%) No response 2 (5%) In non-human primates, PDC
Slide 23: CX-2029: CD71-Directed PDC Clinical Trial Design
2018 2019 CX-2029: CD71-Directed PDC Phase 1 Clinical Trial Design A: DOSE ESCALATION Inclusion: Solid Tumors Dose: TBA C: COHORT EXPANSION(S) B: BIOPSIES REQUIRED Initiation in 3Q 2018 CytomX and AbbVie are co-developing a PDC against CD71, with CytomX leading pre-clinical and early clinical develo
Slide 24: BMS Collaboration CTLA-4 Program: Ipilimumab Probody Program
BMS Collaboration CTLA-4 Program: Ipilimumab (Yervoy®) Probody Program Advancing Ipilimumab 7/10 Tumor Free Ipilimumab Pb-Tx 6/10 Tumor Free Similar Efficacy in Mice HNSTD* in cynos 10 mg/kg ipilimumab 50 mg/kg ipilimumab Pb-Tx * Highest non-severely toxic dose Improved Safety Clinical Study Ongoing
Slide 25: Continued Strong Execution Across Platform and Pipeline
PROCLAIM-CX-072 Updates (Parts A, A2 and B): 2H’18 Updates (Parts C and D): 2019 PROCLAIM-CX-2009 Update (Part A): 2H’18 Update (Part A2): 1H’19 BMS-986249 BMS Responsible for Data Disclosures CX-2029 Clinical Trial Initiation: 3Q 2018 CX-188 IND Filing in 2H’18 Continued Strong Execution Across Pla
Slide 26: Thank you
rT si. e, VTL ™ Z \ 1O JN } { a ¥ THERAPEUTICS a \ Thank you
CytomX Therapeutics — Bank of America Merrill Lynch 2018 Health Care Conference on 6ix